Lenvima 4 -US (Lenvatinib Capsule) 4mg

Lenvatinib 4mg capsules are an oral targeted therapy used for certain types of thyroid cancer and advanced kidney cancer. This prescription medication belongs to the tyrosine kinase inhibitor class, available in 30-count bottles for convenient home use.

Strength

4mg

Pack Size

30s

Storage

Ambient

Manufacturer / TM Owner

Eisai Inc.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Lenvatinib is prescribed to treat progressive, differentiated thyroid cancer that no longer responds to radioactive iodine treatment. It is also used for advanced renal cell carcinoma when combined with everolimus, targeting cancer progression. Patients often ask what is lenvatinib used for, and it is primarily indicated for these specific oncology indications under medical supervision.

Side Effects

Common effects may include fatigue, diarrhea, decreased appetite, or weight loss during treatment. Some patients report nausea or high blood pressure as their bodies adjust to the medication. These effects vary by individual and should be monitored by a healthcare provider.

Precautions & Warnings

Store lenvatinib capsules at room temperature away from moisture and heat. Keep the bottle tightly closed when not in use to maintain potency. Always handle with care and avoid crushing or splitting capsules to prevent exposure. Return unused medication to a pharmacy for proper disposal.

Avoid Interactions

Lenvatinib may interact with strong CYP3A4 inhibitors or inducers, which can alter its effectiveness. Grapefruit products and certain supplements may also affect how the drug works. Patients should discuss all medications, including over-the-counter and herbal products, with their doctor before starting treatment.

Frequently Asked Questions

Lenvatinib is primarily used to treat certain types of thyroid cancer and advanced kidney cancer under medical supervision.

Store lenvatinib capsules at room temperature in a tightly closed bottle away from moisture and heat.

No, capsules should not be opened, crushed, or split to avoid exposure to the medication.

Common side effects may include fatigue, diarrhea, decreased appetite, or weight loss during treatment.

Yes, it may interact with CYP3A4 inhibitors or inducers, grapefruit products, and certain supplements.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.